1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Celgene to acquire Abraxis Bioscience for $2.9 billion up front

 
• By Sukaina Virji

Celgene is to acquire Abraxis Bioscience for $2.9 billion up front in a deal aimed at boosting its oncology presenceby immediate entry into solid tumours, building on Celgene's blood cancers business.

Celgene is to acquire Abraxis Bioscience for $2.9 billion up front in a deal aimed at boosting its oncology presenceby immediate entry into solid tumours, building on Celgene's blood cancers business.

Under the agreement, each share of Abraxis will be converted into an upfront cash payment of $58.00 and 0.2617 shares...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.